Poniachik J

Language: English
References: 7
Page: 67-68
PDF size: 38.58 Kb.

Text Extraction

Most patients with chronic hepatitis C virus (HCV) infections are asymptomatic or display few symptoms, but some experience adverse reactions to therapy. The severity of these adverse effects depends mainly on drug dosage, frequency of administration, and route of administration. Severe reactions to treatment are experienced in 10%–15% of cases.

REFERENCES

1. Keating GM, Curran MP. Peginterferon-α-2a (40 kD) plus Ribavirin 1. Drugs 2003; 63(7): 701-30.

2. Curry MP, Afdhal NH. Use of growth factors with antiviral therapy for chronic hepatitis C. Clin Liver Dis 2005; 9(3): 439-51.

3. Soza A, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K, Park Y, Liang TJ, Hoofnagle JH. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002; 36(5): 1273-9.

4. Afdhal NH. Role of epoetin (OK) alfa in maintaining ribavirin dose. Gastroenterol Clin North Am 2004; 33(suppl): S25-S35

5. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37: 443-51.

6. Schaefer M, Schwaiger M, Garkisch AS, Pich M, Hinzpeter A, Uebelhack R, Heinz A, van Boemmel F, Berg T. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005; 42(6): 793-8.

7. Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM, Nemeroff CB, Miller AH. Depression during pegylated interferon-alpha plus Ribavirin therapy: prevalence and prediction. J Clin Psychiatry 2005; 66(1): 41-8.